

AGILENT TECHNOLOGIES, INC.



Company Overview

Agilent Technologies, Inc. (“Agilent”) designs, manufactures, and sells analytical instruments, consumables, software, and laboratory services for the life sciences, diagnostics, and applied chemical markets. Its three operating groups are **Life Sciences & Applied Markets (LSAM)**, **Diagnostics & Genomics (DGG)**, and **Agilent CrossLab (ACG)**. The company provides solutions across pharmaceuticals, biotechnology, food safety, environmental, forensics, academia, and government sectors.

Agilent’s strategic focus centers on expanding recurring revenue from consumables, software, and services, supported by innovation in chromatography, mass spectrometry, and pathology automation. Its “One Agilent” model integrates instruments, data systems, and consumables to deliver higher lab productivity.

Headquarters: Santa Clara, California

Global Operations: More than 30 manufacturing sites and 40 customer service centers across North America, Europe, and Asia-Pacific.

Employees: Approximately 18,000 worldwide.

1. Top 5 Competitors

- Thermo Fisher Scientific (TMO) – Diversified life-science tools and analytical instruments.
- Danaher Corp. (DHR) – Platforms spanning bioprocessing, diagnostics, and analytical instruments.
- Waters Corp. (WAT) – Specializes in LC/GC/MS and materials analysis.
- Bruker Corp. (BRKR) – Advanced mass spectrometry and NMR spectroscopy.
- Revvity (RVTY, formerly PerkinElmer) – Life-science discovery and diagnostic solutions.

2. Largest Institutional Shareholders

Institutional Ownership Breakdown (latest 13F filings, quarter ended June 30, 2025)

AGILENT TECHNOLOGIES, INC.



Shareholder	Approx. % Ownership	Shares (Millions)
Vanguard Group Inc.	~10.1%	Largest holder; mix of index and active strategies
BlackRock Inc.	~8.9%	Includes ESG and core science-focused ETFs
State Street Corp.	~6.5%	Indexed exposure via SPDR funds
MFS (Massachusetts Financial Services)	~5.8%	Long-term fundamental holding
Wellington Management	~5.2%	Global healthcare and innovation strategy
T. Rowe Price Associates	~4.9%	Active growth funds
Capital World Investors	~4.5%	Large-cap growth and GARP exposure
Geode Capital Management	~2.7%	Passive index tracking
JPMorgan Investment Management	~2.5%	Growth and core healthcare exposure
Morgan Stanley Investment Management	~2.0%	Diversified innovation allocation

Total Institutional Ownership: ~91%

Top 10 Institutions Combined: ~53% of total outstanding shares.



3. Management Team

- Padraig McDonnell — President & Chief Executive Officer.
- Simon May — SVP; President, Life Sciences & Diagnostics Markets Group.
- Mike Zhang — SVP; President, Applied Markets Group.
- Angelica Riemann — SVP; President, Agilent CrossLab Group.
- Jonah Kirkwood — SVP; Chief Commercial Officer.
- Bret DiMarco — SVP; Chief Legal Officer & Secretary.
- Meghan Henson — SVP; Chief Human Resources Officer.
- August (Gus) Specht — SVP; Chief Technology Officer.
- Fred Schwarz — SVP; Chief Strategy & Corporate Development Officer.
- Rodney Gonsalves — VP; Corporate Controller & Principal Accounting Officer.
- Guillermo Gualino — VP; Treasurer.

4. Revenue

- FY2024 (year ended Oct. 31, 2024): Total net revenue \$6.51 billion — LSAM \$3.215B (49%), DGG \$1.651B (25%), ACG \$1.644B (25%).
- Q3 FY2025 (ended July 31, 2025): Revenue \$1.74 billion (+10.1% reported, +6.1% core), EPS \$1.37, operating margin 25.1%.
- FY2025 Guidance: Revenue \$6.9–6.93 billion, EPS \$5.56–5.59, core growth 4.3–4.6%, operating cash flow \$450 million.

5. Institutions with Buy Recommendations

Recent “Buy/Overweight/Outperform” calls include:

- UBS — Buy, PT **\$170** (Oct 2025).
- TD Cowen — Buy, reiterated PT **\$165** (Oct 2025).
- JPMorgan — Buy, reaffirmed (Oct 2025).
- Rothschild Redburn — Buy, PT **\$165** (Oct 2025).
- Barclays — Overweight, PT **\$160** (Sep 2025).
- Oppenheimer — Outperform, PT **\$165** (Sep 2025).

6. Analyst Sentiment Summary

- **Consensus Rating:** Moderate Buy.
- **Average Price Target:** ~\$149; range \$116–\$170.
- **Coverage:** 21 analysts — 13 Buy/Outperform, 6 Hold, 2 Sell.
- Analysts highlight robust recurring revenue (~55% of total), solid margins (~25%), and steady demand from pharma and chemical markets.
- Argus Research maintains **Hold, PT \$153**, citing near-term normalization but reaffirming long-term earnings strength.



7. Insider Buying and Selling (Last 24 Months)

- Insider activity primarily **sales**, consistent with Rule 10b5-1 trading plans and equity vesting.
- Padraig McDonnell (CEO): Sold 2,000 shares @\$124.88 (Sept 2, 2025); sold 1,911 shares @\$150 (Jan 21, 2025).
- Jonah Kirkwood (SVP) and other executives executed scheduled RSU tax withholdings.
- **No open-market insider purchases** reported during the past 24 months.
- Aggregate insider sales ≈ **\$1.8 million**, all under pre-approved plans.